Neovasc Inc. (NVCN) News
Filter NVCN News Items
NVCN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVCN News Highlights
- For NVCN, its 30 day story count is now at 3.
- Over the past 11 days, the trend for NVCN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- CMS and SWAV are the most mentioned tickers in articles about NVCN.
Latest NVCN News From Around the Web
Below are the latest news stories about NEOVASC INC that investors may wish to consider to help them evaluate NVCN as an investment opportunity.
Why Shares of Shockwave Medical Jumped on TuesdayShares of Shockwave Medical (NASDAQ: SWAV) were up 10.69% early Tuesday afternoon after the Centers for Medicare and Medicaid Services (CMS) unveiled a proposed rule that detailed new payment codes for coronary intravascular lithotripsy (IVL), which is performed by a system that Shockwave manufactures. Shockwave's IVL uses sonic pressure waves to break up hardened plaque in arteries. Not only do the proposed new codes mean more money for Shockwave -- an estimated $4,000 to $5,000 more per procedure -- but it also shows that the CMS is recognizing the value of the IVL. |
Shockwave Medical Completes Acquisition of NeovascSANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”). The Neovasc Reducer System (the “Reducer”) is a first-of-its-kind technology to address refractory angina. Refractory angina is a chronic condition in which a |
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate UpdateVANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million in the fourth quarter of 2022 (91% growth against the fourth quarter of 2021), and $3.8 million for the full year 2022 (49% growth against fiscal 2021). · On March 13, 2023, following the conclusion of oral a |
Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last yearThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you... |
Neovasc Shareholders Approve Acquisition by Shockwave MedicalVancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement |
Neovasc Announces German Reimbursement RenewalVANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedure |
5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaBy Davit Kirakosyan |
Shockwave Medical's (SWAV) New Buyout to Boost Patient OutcomeShockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool. |
Dow Dinged As Big Bank Earnings WeighA round of earnings from the banking sector is weighing today, stifling Wall Street's early 2023 momentum. |
Shockwave Medical Seeks To Bolster Its Cardiovascular Disease Portfolio With Neovasc AcquisitionShockwave Medical Inc (NASDAQ: SWAV) has agreed to acquire Neovasc Inc (NASDAQ: NVCN) for an upfront cash payment of $27.25 per share, corresponding to an enterprise value of approximately $100 million. The upfront cash consideration represents a 27% and 68% premium to the closing price and 30-day VWAP, respectively, of Neovasc's common shares on Jan. 13, 2023. Neovasc shareholders will also receive a potential deferred payment in the form of a non-tradable contingent value right (CVR), entitlin |